Galectin Therapeutics. Earnings Calls

Mar 30, 2025
-$0.190 (-18.75%)
Release date Mar 31, 2025
EPS estimate -$0.160
EPS actual -$0.190
EPS Surprise -18.75%
Revenue estimate -
Revenue actual -
Dec 31, 2024
Release date Mar 28, 2025
EPS estimate -
EPS actual -$0.192
Revenue estimate -
Revenue actual -
Sep 30, 2024
-$0.180 (10.00%)
Release date Nov 14, 2024
EPS estimate -$0.200
EPS actual -$0.180
EPS Surprise 10.00%
Revenue estimate -
Revenue actual -
Jun 30, 2024
-$0.200 (-25.00%)
Release date Aug 13, 2024
EPS estimate -$0.160
EPS actual -$0.200
EPS Surprise -25.00%
Revenue estimate -
Revenue actual -

Last 4 Quarters for Galectin Therapeutics.

Below you can see how GALT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Jun 30, 2024 Missed
Release date Aug 13, 2024
Price on release $2.25
EPS estimate -$0.160
EPS actual -$0.200
EPS surprise -25.00%
Date Price
Aug 07, 2024 $2.10
Aug 08, 2024 $2.14
Aug 09, 2024 $2.04
Aug 12, 2024 $2.11
Aug 13, 2024 $2.25
Aug 14, 2024 $2.08
Aug 15, 2024 $2.19
Aug 16, 2024 $2.32
Aug 19, 2024 $2.35
4 days before 7.14%
4 days after 4.44%
On release day -7.56%
Change in period 11.90%
Sep 30, 2024 Beat
Release date Nov 14, 2024
Price on release $2.75
EPS estimate -$0.200
EPS actual -$0.180
EPS surprise 10.00%
Date Price
Nov 08, 2024 $3.00
Nov 11, 2024 $2.89
Nov 12, 2024 $2.96
Nov 13, 2024 $2.90
Nov 14, 2024 $2.75
Nov 15, 2024 $2.77
Nov 18, 2024 $2.69
Nov 19, 2024 $2.76
Nov 20, 2024 $2.82
4 days before -8.33%
4 days after 2.55%
On release day 0.727%
Change in period -6.00%
Dec 31, 2024
Release date Mar 28, 2025
Price on release $1.52
EPS estimate -
EPS actual -$0.192
Date Price
Mar 24, 2025 $1.65
Mar 25, 2025 $1.77
Mar 26, 2025 $1.64
Mar 27, 2025 $1.68
Mar 28, 2025 $1.52
Mar 31, 2025 $1.22
Apr 01, 2025 $1.26
Apr 02, 2025 $1.32
Apr 03, 2025 $1.28
4 days before -7.88%
4 days after -15.79%
On release day -19.74%
Change in period -22.42%
Mar 30, 2025 Missed
Release date Mar 31, 2025
Price on release $1.22
EPS estimate -$0.160
EPS actual -$0.190
EPS surprise -18.75%
Date Price
Mar 25, 2025 $1.77
Mar 26, 2025 $1.64
Mar 27, 2025 $1.68
Mar 28, 2025 $1.52
Mar 31, 2025 $1.22
Apr 01, 2025 $1.26
Apr 02, 2025 $1.32
Apr 03, 2025 $1.28
Apr 04, 2025 $1.32
4 days before -31.07%
4 days after 8.20%
On release day 3.28%
Change in period -25.42%

Galectin Therapeutics. Earnings History

Earnings Calendar

FAQ

When is the earnings report for GALT?
Galectin Therapeutics Inc. (GALT) has scheduled its earnings report for Aug 11, 2025 after the markets close.

What is the GALT price-to-earnings (P/E) ratio?
GALT P/E ratio as of Jun 20, 2025 (TTM) is -4.60.

What is the GALT EPS forecast?
The forecasted EPS (Earnings Per Share) for Galectin Therapeutics Inc. (GALT) for the first fiscal quarter 2025 is $.

What are Galectin Therapeutics Inc.'s retained earnings?
On its balance sheet, Galectin Therapeutics Inc. reported retained earnings of $0 for the latest quarter ending Mar 30, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT GALECTIN THERAPEUTICS INC.
Galectin Therapeutics.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatiti...
GOLDEN STAR
Ticker Change Signal Date
G
GTM
$9.57
1.78% Jun 02
TAC
$8.90
27.87% May 12
UAA
$5.84
5.65% May 09
MEDP
$300.81
0.625% May 08
P
PENG
$17.23
14.80% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE